Pan Tumor Rollover Study | BMS Clinical Trials

Study Arms

Experimental: A1: Nivolumab Monotherapy Dose 1

ASSIGNED INTERVENTION

Drug: Nivolumab

Study Arms

Experimental: A2: Nivolumab Monotherapy Dose 2

ASSIGNED INTERVENTION

Drug: Nivolumab

Study Arms

Experimental: B1: Nivolumab + Ipilimumab

ASSIGNED INTERVENTION

Drug: Ipilimumab, Nivolumab

Study Arms

Experimental: B2: Nivolumab + Ipilimumab + Cabozantinib

ASSIGNED INTERVENTION

Drug: Ipilimumab, Cabozantinib, Nivolumab

Study Arms

Experimental: B3: Nivolumab + Ipilimumab + Trametinib

ASSIGNED INTERVENTION

Drug: Ipilimumab, Trametinib, Nivolumab

Study Arms

Experimental: C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1

ASSIGNED INTERVENTION

Drug: Nivolumab + Relatlimab

Study Arms

Experimental: C10: Relatlimab + Nivolumab SAV Dose 4

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C11: Relatlimab + Nivolumab SAV + PDCT Dose 2

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C12: Relatlimab + Nivolumab SAV Dose 5

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2

ASSIGNED INTERVENTION

Drug: Nivolumab + Relatlimab

Study Arms

Experimental: C4: Relatlimab + Nivolumab SAV Dose 2

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C5: Relatlimab + Nivolumab + Ipilimumab

ASSIGNED INTERVENTION

Drug: Ipilimumab, Nivolumab

Study Arms

Experimental: C6: Relatlimab + Nivolumab + Capecitabine

ASSIGNED INTERVENTION

Drug: Nivolumab + Relatlimab, Capecitabine

Study Arms

Experimental: C7: Relatlimab + Nivolumab SAV Dose 3

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C8: Relatlimab + Nivolumab SAV + PDCT Dose 1

ASSIGNED INTERVENTION

Drug: Relatlimab, Nivolumab

Study Arms

Experimental: C9: Relatlimab + Nivolumab SAV + Bevacizumab

ASSIGNED INTERVENTION

Drug: Relatlimab, Bevacizumab, Nivolumab

Study Arms

Experimental: D1: Nivolumab + Temozolomide

ASSIGNED INTERVENTION

Drug: Temozolomide, Nivolumab

Study Arms

Experimental: D2: Nivolumab + Rucaparib

ASSIGNED INTERVENTION

Drug: Rucaparib, Nivolumab

Study Arms

Experimental: D3: Nivolumab + Daratumumab

ASSIGNED INTERVENTION

Drug: Daratumumab, Nivolumab

Study Arms

Experimental: D4: Nivolumab + Bevacizumab

ASSIGNED INTERVENTION

Drug: Nivolumab

Study Arms

Experimental: E1: Bevacizumab Monotherapy

ASSIGNED INTERVENTION

Drug: Bevacizumab

Study Arms

Experimental: E10: Pemetrexed Monotherapy

ASSIGNED INTERVENTION

Drug: Pemetrexed

Study Arms

Experimental: E11: Pembrolizumab Monotherapy

ASSIGNED INTERVENTION

Drug: Pembrolizumab

Study Arms

Experimental: E2: Regorafinib Monotherapy

ASSIGNED INTERVENTION

Drug: Regorafinib

Study Arms

Experimental: E3: Leucovorin + Fluorouracil

ASSIGNED INTERVENTION

Drug: Leucovorin

Study Arms

Experimental: E4: Leucovorin + Oxaliplatin + Fluorouracil

ASSIGNED INTERVENTION

Drug: Leucovorin, Fluorouracil, Oxaliplatin

Study Arms

Experimental: E5: Enzalutamide Monotherapy

ASSIGNED INTERVENTION

Drug: Enzalutamide

Study Arms

Experimental: E6: Sunitinib Monotherapy

ASSIGNED INTERVENTION

Drug: Sunitinib

Study Arms

Experimental: E7: Rucaparib Monotherapy

ASSIGNED INTERVENTION

Drug: Rucaparib

Study Arms

Experimental: E8: Capecitabine Monotherapy

ASSIGNED INTERVENTION

Drug: Capecitabine

Study Arms

Experimental: E9: Cabozantinib Monotherapy

ASSIGNED INTERVENTION

Drug: Cabozantinib

Trial ID CA209-8TT | NCT03899155

Summary

Overview

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you